Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 01

114P - Clinical interchangeability of programmed cell death-ligand 1 (PD-L1) immunohistochemistry (IHC) assays for the treatment of first-line (1L) non-small cell lung cancer (NSCLC) with cemiplimab

Date

10 Sep 2022

Session

Poster session 01

Presenters

Keith Kerr

Citation

Annals of Oncology (2022) 33 (suppl_7): S27-S54. 10.1016/annonc/annonc1037

Authors

K.M. Kerr1, J. Perez2, K. McGuire2, B. Baker2, F. Fang3, J. Li3, G. Wlasiuk4, S. Li2, B. Gao2, J. Pouliot5, F. Seebach2, I. Lowy2, G. Gullo5, P. Rietschel2

Author affiliations

  • 1 Department Of Pathology, Aberdeen University Medical School, University of Aberdeen, AB25 2ZN - Aberdeen/GB
  • 2 Clinical Sciences, Regeneron Pharmaceuticals, Inc., Tarrytown/US
  • 3 Clinical Science, Roche Molecular Solutions, Pleasanton/US
  • 4 Diagnostics, Roche Tissue Diagnostics, Tuscon/US
  • 5 Clinical Sciences, Regeneron Pharmaceuticals, Inc., 10591 - Tarrytown/US
More

Abstract 114P

Background

Multiple PD-L1 IHC assays have been developed independently targeting the PD-1/PD-L1 axis. The lack of harmonisation has created undue complexity for clinicians who use PD-L1 tests to guide treatment decisions. In this first-of-its-kind bridging study in 1L NSCLC, we demonstrate clinical agreement of two PD-L1 IHC assays using samples from pts treated with 1L cemiplimab in the phase III EMPOWER-Lung 1 study (NCT03088540).

Methods

EMPOWER-Lung 1 used the PD-L1 IHC 22C3 pharmDx assay (Agilent Technologies) for patient (pt) selection. A total of 871 pts samples were retrospectively tested with the VENTANA PD-L1 (SP263) CDx Assay (Roche), including 481 enrolled pts (PD-L1 ≥50%) and a random subset of 390 screen-failed pts (PD-L1 <50%). Concordance between the assays was evaluated. Efficacy (overall survival [OS], progression-free survival [PFS]) was estimated in the PD-L1 ≥50% SP263+ population (including 22C3+/SP263+ and 22C3-/SP263+ subpopulations) and compared with results from the 22C3+ population.

Results

Overall concordance was 88%. Efficacy in the 22C3+/SP263+ population for cemiplimab vs platinum-doublet chemotherapy (OS hazard ratio [HR] 0.52, 95% confidence interval [CI] 0.34–0.80]; PFS HR 0.43, 95% CI 0.32–0.59) was similar to efficacy in the 22C3+ population (Table). Additional sensitivity analysis showed results in the overall SP263+ population were consistent with the primary analysis. Table: 114P

Endpoints 22C3+ (N=563) 22C3+/SP263+ (N=324)
Cemiplimab(n=283) Chemotherapy(n=280) Cemiplimab(n=164) Chemotherapy(n=160)
OS
Median (95% CI), months NR(17.9–NE) 14.2(11.2–17.5) 22.1(17.7–NE) 15.5(11.4–NE)
HR (95% CI) 0.57 (0.42–0.77) 0.52 (0.34–0.80)
P value 0.0002 0.0022
PFS
Median (95% CI), months 8.2(6.1–8.8) 5.7(4.5–6.2) 9.8(8.1–14.5) 5.4(4.2–6.2)
HR (95% CI) 0.54 (0.43–0.68) 0.43 (0.32–0.59)
P value <0.0001 <0.0001

22C3+: randomised pts with PD-L1 ≥50% by 22C3 assay according to approved labelling from EMPOWER-Lung 1.22C3+/SP263+: pts with PD-L1 ≥50% by SP263 and 22C3 assays, from available samples for retesting. SP263 is not approved and is under FDA review.

Conclusions

Similar efficacy was observed with the 22C3+ and SP263+ populations, demonstrating potential interchangeability of these PD-L1 IHC assays for selecting pts for treatment with 1L cemiplimab monotherapy for advanced NSCLC.

Clinical trial identification

NCT03088540.

Editorial acknowledgement

Editorial support was provided by Sameen Yousaf, PhD, Prime Global, Knutsford, UK, funded by Regeneron Pharmaceuticals, Inc., and Sanofi.

Legal entity responsible for the study

Regeneron Pharmaceuticals, Inc., and Sanofi.

Funding

Regeneron Pharmaceuticals, Inc., and Sanofi.

Disclosure

K.M. Kerr: Financial Interests, Personal, Other, fees for consultancy and/or lecturing: AbbVie, Archer Diagnostics, AstraZeneca, Bayer, Boehringer Ingelheim, Celgene, Debiopharm, Diaceutics, Eli Lilly, Merck Serono, Merck Sharpe & Dohme, Novartis, Pfizer, Regeneron, Roche, Takeda, Ventana, Medscape, PER, Prime Oncology, Springer. J. Perez: Financial Interests, Personal, Full or part-time Employment: Regeneron Pharmaceuticals, Inc.; Financial Interests, Personal, Stocks/Shares: Regeneron Pharmaceuticals, Inc. K. McGuire: Financial Interests, Personal, Full or part-time Employment: Regeneron Pharmaceuticals, Inc.; Financial Interests, Personal, Stocks/Shares: Regeneron Pharmaceuticals, Inc. B. Baker: Financial Interests, Personal, Invited Speaker: Regeneron Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc. F. Fang: Financial Interests, Personal, Full or part-time Employment: Roche Molecular Solutions, Ltd. J. Li: Financial Interests, Personal, Full or part-time Employment: Roche Molecular Solutions, Ltd.; Financial Interests, Personal, Stocks/Shares: F. Hoffmann-La Roche. G. Wlasiuk: Financial Interests, Personal, Full or part-time Employment: Roche Tissue Diagnostics Ltd.; Financial Interests, Personal, Stocks/Shares: F. Hoffmann-La Roche. S. Li: Financial Interests, Personal, Full or part-time Employment: Regeneron Pharmaceuticals, Inc.; Financial Interests, Personal, Stocks/Shares: Regeneron Pharmaceuticals, Inc. B. Gao: Financial Interests, Personal, Full or part-time Employment: Regeneron Pharmaceuticals, Inc.; Financial Interests, Personal, Stocks/Shares: Regeneron Pharmaceuticals, Inc. J. Pouliot: Financial Interests, Personal, Full or part-time Employment: Regeneron Pharmaceuticals, Inc.; Financial Interests, Personal, Stocks/Shares: Regeneron Pharmaceuticals, Inc. F. Seebach: Financial Interests, Personal, Full or part-time Employment: Regeneron Pharmaceuticals, Inc.; Financial Interests, Personal, Stocks/Shares: Regeneron Pharmaceuticals, Inc. I. Lowy: Financial Interests, Personal, Full or part-time Employment: Regeneron Pharmaceuticals, Inc.; Financial Interests, Personal, Stocks/Shares: Regeneron Pharmaceuticals, Inc. G. Gullo: Financial Interests, Personal, Stocks/Shares: Regeneron Pharmaceuticals Inc.; Financial Interests, Personal, Full or part-time Employment: Regeneron Pharmaceuticals Inc. P. Rietschel: Financial Interests, Personal, Full or part-time Employment: Regeneron Pharmaceuticals, Inc.; Financial Interests, Personal, Stocks/Shares: Regeneron Pharmaceuticals, Inc.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.